Anti-non-muscle Myosin IIA antibody (ab24762)

Overview

• Product nameAnti-non-muscle Myosin IIA antibodySee all non-muscle Myosin IIA primary antibodies ...
• Description
  Rabbit polyclonal to non-muscle Myosin IIA
• Tested applicationsIHC-Fr, IHC-P, WB, ICC/IF, IP, Flow Cyt, ICC more details
• Species reactivity
  Reacts with: Mouse, Rat, Hamster, Cow, Human
  
• Immunogen

  Synthetic peptide: GKADGAEAKPAE, corresponding to C terminal amino acids 1948/1959 of Human non-muscle Myosin IIA

  Run BLAST with Run BLAST with
• Epitopeab24762 reacts with an epitope located in the C terminus of Myosin IIA.

Properties

• FormLiquid
• Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
• Storage bufferPreservative: 0.03% Thimerosal (merthiolate)
  Constituents: Tris buffered saline
• Concentration information loading...
• PurityIgG fraction
• Purification notesab24762 is an affinity purified IgG.
• Clonality Polyclonal
• IsotypeIgG
• Research Areas
  • Signal Transduction
  • Cytoskeleton / ECM
  • Cytoskeleton
  • Motor Proteins
  • Myosin

Applications

Target

• FunctionCellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as secretion and capping.
• Tissue specificityIn the kidney, expressed in the glomeruli. Also expressed in leukocytes.
• Involvement in diseaseDefects in MYH9 are the cause of May-Hegglin anomaly (MHA) [MIM:155100]. MHA is an autosomal dominant macrothrombocytopenia characterized by thrombocytopenia, giant platelets and leukokyte inclusions appearing as highly parallel paracrystalline bodies.
  Defects in MYH9 are the cause of Sebastian syndrome (SBS) [MIM:605249]. SBS is an autosomal dominant macrothrombocytopenia characterized by thrombocytopenia, giant platelets and leukocyte inclusions that are smaller and less organized than in May-Hegglin anomaly.
  Defects in MYH9 are the cause of Fechtner syndrome (FTNS) [MIM:153640]. FTNS is an autosomal dominant macrothrombocytopenia characterized by thrombocytopenia, giant platelets and leukocyte inclusions that are small and poorly organized. Additionally, FTNS is distinguished by Alport-like clinical features of sensorineural deafness, cataracts and nephritis.
  Defects in MYH9 are the cause of Alport syndrome with macrothrombocytopenia (APSM) [MIM:153650]. APSM is an autosomal dominant disorder characterized by the association of ocular lesions, sensorineural hearing loss and nephritis (Alport syndrome) with platelet defects.
  Defects in MYH9 are the cause of Epstein syndrome (EPS) [MIM:153650]. EPS is an autosomal dominant disorder characterized by the association of macrothrombocytopathy, sensorineural hearing loss and nephritis.
  Defects in MYH9 are the cause of deafness autosomal dominant type 17 (DFNA17) [MIM:603622]. DFNA17 is a form of sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. DFNA17 is characterized by progressive hearing impairment and cochleosaccular degeneration.
  Defects in MYH9 are the cause of macrothrombocytopenia with progressive sensorineural deafness (MPSD) [MIM:600208]. MPSD is an autosomal dominant disorder characterized by the association of macrothrombocytopathy and progressive sensorineural hearing loss without renal dysfunction.
  Note=Subjects with mutations in the motor domain of MYH9 present with severe thrombocytopenia and develop nephritis and deafness before the age of 40 years, while those with mutations in the tail domain have a much lower risk of noncongenital complications and significantly higher platelet counts. The clinical course of patients with mutations in the four most frequently affected residues of MYH9 (responsible for 70% of MYH9-related cases) were evaluated. Mutations at residue 1933 do not induce kidney damage or cataracts and cause deafness only in the elderly, those in position 702 result in severe thrombocytopenia and produce nephritis and deafness at a juvenile age, while alterations at residue 1424 or 1841 result in intermediate clinical pictures.
  Note=Genetic variations in MYH9 are associated with non-diabetic end stage renal disease (ESRD).
• Sequence similaritiesContains 1 IQ domain.
  Contains 1 myosin head-like domain.
• DomainThe rodlike tail sequence is highly repetitive, showing cycles of a 28-residue repeat pattern composed of 4 heptapeptides, characteristic for alpha-helical coiled coils.
• Post-translational
  modificationsISGylated.

Target information above from: UniProt accession P35579 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010) .

Information by UniProt
• Database links
  • Entrez Gene: 404108 Cow
  • Entrez Gene: 4627 Human
  • Entrez Gene: 17886 Mouse
  • Entrez Gene: 25745 Rat
  • Omim: 160775 Human
  • SwissProt: P35579 Human
  • SwissProt: Q8VDD5 Mouse
  • SwissProt: Q62812 Rat

  • Unigene: 474751 Human
  • Unigene: 29677 Mouse
  • Unigene: 11385 Rat

  see all

• Alternative names
  BDPLT 6 antibodyBDPLT6 antibodyCellular myosin heavy chain antibody

  Cellular myosin heavy chain type A antibodyDFNA 17 antibodyDFNA17 antibodyEPSTS antibodyFTNS antibodyMGC104539 antibodyMHA antibodyMYH 2A antibodyMYH 9 antibodyMYH2A antibodyMYH2A antibodyMYH9 antibodyMYH9_HUMAN antibodyMYHas8 antibodyMYHas8 antibodyMyHC 2A antibodyMyHC IIa antibodyMyHC-2A antibodyMyHC-2A antibodyMyHC-IIa antibodyMyHC-IIa antibodyMyHC2A antibodyMyHCIIa antibodyMYHSA 2 antibodyMYHSA2 antibodyMYHSA2 antibodyMyosin 9 antibodyMyosin heavy chain 9 antibodyMyosin heavy chain 9 non muscle antibodyMyosin heavy chain antibodyMyosin heavy chain non muscle IIa antibodyMyosin heavy chain nonmuscle IIa antibodymyosin heavy polypeptide 2 antibodymyosin heavy polypeptide 2 antibodyMyosin heavy polypeptide 9 non muscle antibodyMyosin-9 antibodyMyosin9 antibodyNMHC II A antibodyNMMHC A antibodyNMMHC II a antibodyNMMHC II-a antibodyNMMHC IIA antibodyNMMHC-A antibodyNMMHC-IIA antibodyNMMHCA antibodyNon muscle myosin heavy chain A antibodyNon muscle myosin heavy chain antibodyNon muscle myosin heavy chain II A antibodyNon muscle myosin heavy polypeptide 9 antibodynon-muscle IIa antibodyNon-muscle myosin heavy chain A antibodyNon-muscle myosin heavy chain IIa antibodyNonmuscle myosin heavy chain A antibodyNonmuscle myosin heavy chain II A antibodytype A antibody

  see all

Anti-non-muscle Myosin IIA antibody images

• 

  Western blot - non-muscle Myosin IIA antibody (ab24762)
  Anti-non-muscle Myosin IIA antibody (ab24762) at 1/1000 dilution + Rat PC12 whole cell lysate at 20 µg
  
  Secondary
  HRP conjugated swine anti-rabbit
  developed using the ECL technique
  
  Performed under reducing conditions.
  
  Predicted band size : 226 kDa
  Observed band size : 220 kDa (why is the actual band size different from the predicted?)
  
  
  Exposure time : 2 minutes

  This image is courtesy of an anonymous Abreview

  See Abreview

• 

  Immunocytochemistry/ Immunofluorescence - non-muscle Myosin IIA antibody (ab24762)This image is courtesy of an anonymous Abreview
  ab24762 staining non-muscle Myosin IIA in Human fibrosarcoma cells by ICC/IF (Immunocytochemistry/immunoflurescence). Cells were fixed with paraformaldehyde and permeabilized with 0.1% Triton X-10. Samples were incubated with 10 µg/ml primary antibody in PBS for 1 hour at 20°C. An Alexa Fluor^® 555-conjugated Donkey polyclonal to rabbit IgG, dilution 1/500, was used as secondary antibody. Nuclei were counterstained with DAPI.

  See Abreview

• 

  Flow Cytometry - non-muscle Myosin IIA antibody (ab24762)This image is courtesy of an Abreview by Mahesh Shivananjappa.
  ab24762 detecting non-muscle Myosin IIA in Human platelets by Flow Cytometry. Platelets were isolated by spinning Platelet rich plasma on Histopaque. Cells were fixed in PFA and permeabilized in 0.1% Triton-X100 in 2% BSA for 30 minutes. The primary antibody was diluted 1/200 in 2% BSA in PBS and incubated with the sample for 18 hours at 4°C. An Alexa Fluor® 488-conjugated Chicken anti-Rabbit IgG (H+L) antibody, diluted 1/500 was used as the secondary antibody.

  Abbreviations in the figure:
  US Unstained, Red Peak;
  IgG Rb: IgG Rabbit (Isotype Control), Blue Peak;
  Myosin: Myosin IIA, Green Peak.

  See Abreview

• 

  Immunocytochemistry/ Immunofluorescence - non-muscle Myosin IIA antibody (ab24762)This image is courtesy of an anonymous Abreview
  ab24762 staining non-muscle Myosin IIA in Human embryonic stem cells by ICC/IF (Immunocytochemistry/immunoflurescence). Cells were fixed with paraformaldehyde,permeabilized with 0.5% Triton X-100 and blocked with 10% serum for 1 hour at room temperature. Samples were incubated with primary antibody (1/400 in PBS + 0.05% Tween20) for 1 hour at room temperature. A DyLight^® 488-conjugated Donkey polyclonal to rabbit IgG, dilution 1/200, was used as the secondary antibody.

  See Abreview